A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

Inclusion Criteria: * Histologically confirmed metastatic 1L Stage IV non-small cell lung cancer (NSCLC) of squamous or nonsquamous histology * No prior systemic anti-cancer treatment given as primary therapy for advanced or metastatic NSCLC * Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * A formalin-fixed, paraffin-embedded (FFPE) tumor tissue block or a minimum of 20 unstained slides of tumor tissue obtained during screening or prior to enrollment * Life expectancy of at least 3 months at the time of first dose Exclusion Criteria: * Participants with epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or c-ros oncogene 1 (ROS-1) mutations which are sensitive to available targeted inhibitor therapy. Participants with nonsquamous histology and unknown EGFR, ALK, or ROS-1 status are also excluded * Participants with known B-rapidly accelerated fibrosarcoma proto-oncogene (BRAF) V600E mutations that are sensitive to available targeted inhibitor therapy. Participants with unknown or indeterminate BRAF mutation status are eligible. * Untreated central nervous system metastases * Leptomeningeal metastases (carcinomatous meningitis) * Concurrent malignancy requiring treatment * Active, known, or suspected autoimmune disease * Interstitial lung disease * Uncontrolled or significant cardiovascular disease Other protocol-defined inclusion/exclusion criteria apply